Aurigene Oncology Limited reported initial results from its Phase 1 clinical trial of AUR112, an oral drug candidate for treating ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE